Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers

Ekins, 1999, The role of CYP2B6 in human xenobiotic metabolism, Drug Metab Rev, 31, 719, 10.1081/DMR-100101942 Hodgson, 2007, The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals, Pharmacol Ther, 113, 420, 10.1016/j.pharmthera.2006.10.002 Wang, 2008, CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme, Curr Drug Metab, 9, 598, 10.2174/138920008785821710 Mo, 2009, Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6, Curr Drug Metab, 10, 730, 10.2174/138920009789895534 Turpeinen, 2012, Cytochrome P450 2B6: function, genetics, and clinical relevance, Drug Metabol Drug Interact, 27, 185, 10.1515/dmdi-2012-0027 Zanger, 2013, Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance, Front Genet, 4, 1, 10.3389/fgene.2013.00024 Zanger, 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance, Pharmacogenomics, 8, 743, 10.2217/14622416.8.7.743 Li, 2012, Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment, Pharmacogenomics, 13, 555, 10.2217/pgs.11.160 Turpeinen, 2006, The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico, Curr Drug Metab, 7, 705, 10.2174/138920006778520633 Faucette, 2000, Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity, Drug Metab Dispos, 28, 1222 Xu, 2007, Stereoselective analysis of hydroxybupropion and application to drug interaction studies, Chirality, 19, 163, 10.1002/chir.20356 Kirchheiner, 2003, Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6, Pharmacogenetics, 13, 619, 10.1097/00008571-200310000-00005 Skarydova, 2014, Deeper insight into the reducing biotransformation of bupropion in the human liver, Drug Metab Pharmacokinet, 29, 177, 10.2133/dmpk.DMPK-13-RG-051 Chen, 2010, The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19, Xenobiotica, 40, 536, 10.3109/00498254.2010.492880 Kharasch, 2008, Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity, J Clin Pharmacol, 48, 464, 10.1177/0091270008314254 Ward, 2003, The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity, J Pharmacol Exp Ther, 306, 287, 10.1124/jpet.103.049601 Ogburn, 2010, Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 (CYP) 2A6 as the principal catalyst of efavirenz 7-hydroxylation, Drug Metab Dispos, 38, 1218, 10.1124/dmd.109.031393 Desta, 2007, Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro, Pharmacogenomics, 8, 547, 10.2217/14622416.8.6.547 Mutlib, 1999, Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz, Drug Metab Dispos, 27, 1319 Tsuchiya, 2004, Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens, Biochem Biophys Res Commun, 319, 1322, 10.1016/j.bbrc.2004.05.116 Haas, 2004, Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study, AIDS, 18, 2391 2012 2012 Rae, 2001, Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays, J Pharmacol Exp Ther, 299, 849 Faucette, 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers, Drug Metab Dispos, 32, 348, 10.1124/dmd.32.3.348 Kharasch, 2004, Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone, Clin Pharmacol Ther, 76, 250, 10.1016/j.clpt.2004.05.003 Noppers, 2011, Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration, Anesthesiology, 114, 1435, 10.1097/ALN.0b013e318218a881 Lopez-Cortes, 2002, Pharmacokinetic interactions between efavirenz and rifampicin in HIV- infected patients with tuberculosis, Clin Pharmacokinet, 41, 681, 10.2165/00003088-200241090-00004 Cohen, 2009, Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G > T polymorphism on efavirenz concentrations in adults in South Africa, Antivir Ther, 14, 687, 10.1177/135965350901400502 Dooley, 2015, Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection, J Infect Dis, 211, 197, 10.1093/infdis/jiu429 Kwara, 2011, Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy, AIDS, 25, 388, 10.1097/QAD.0b013e3283427e05 Meyer zu Schwabedissen, 2012, Compartment-specific gene regulation of the CAR inducer efavirenz in vivo, Clin Pharmacol Ther, 92, 103, 10.1038/clpt.2012.34 Koh, 2012, Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy, Biochem Pharmacol, 84, 93, 10.1016/j.bcp.2012.03.016 McIlleron, 2012, Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines, Antimicrob Agents Chemother, 56, 3232, 10.1128/AAC.05526-11 Kim, 2011, Rapid and simultaneous determination of efavirenz, 8-hydroxyefavirenz, and 8,14-dihydroxyefavirenz using LC–MS–MS in human plasma and application to pharmacokinetics in healthy volunteers, Chromatographia, 73, 263, 10.1007/s10337-010-1882-5 Blievernicht, 2007, MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms, Clin Chem, 53, 24, 10.1373/clinchem.2006.074856 Lang, 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver, Pharmacogenetics, 11, 399, 10.1097/00008571-200107000-00004 2015 Yenny, 2011, Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers, Int J Clin Pharmacol Ther, 49, 162, 10.5414/CP201473 Jiang, 2013, Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl-metabolites: exploration of a novel CYP2B6 phenotyping index, Br J Clin Pharmacol, 75, 244, 10.1111/j.1365-2125.2012.04314.x Luetkemeyer, 2013, Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study, Clin Infect Dis, 57, 586, 10.1093/cid/cit246 McIlleron, 2013, Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype, AIDS, 27, 1933, 10.1097/QAD.0b013e328360dbb4 Boulle, 2008, Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy, JAMA, 300, 530, 10.1001/jama.300.5.530 Friedland, 2006, Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV, J Antimicrob Chemother, 58, 1299, 10.1093/jac/dkl399 Manosuthi, 2009, A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study, Clin Infect Dis, 48, 1752, 10.1086/599114 Niemi, 2003, Pharmacokinetic interactions with rifampicin: clinical relevance, Clin Pharmacokinet, 42, 819, 10.2165/00003088-200342090-00003 Mukonzo, 2009, A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans, Br J Clin Pharmacol, 68, 690, 10.1111/j.1365-2125.2009.03516.x Lamba, 2003, Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression, J Pharmacol Exp Ther, 307, 906, 10.1124/jpet.103.054866 Hofmann, 2008, Aberrant splicing caused by single nucleotide polymorphism c.516G > T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver, J Pharmacol Exp Ther, 325, 284, 10.1124/jpet.107.133306 Burger, 2006, Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism, Br J Clin Pharmacol, 61, 148, 10.1111/j.1365-2125.2005.02536.x Ngaimisi, 2010, Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients, Clin Pharmacol Ther, 88, 676, 10.1038/clpt.2010.172